Today’s Top Biotech Stories: Insmed, Exelixis, United Therapeutics, and Alnylam

Insmed, Exelixis, United Therapeutics, and Alnylam could all make biotech headlines this morning. Here’s why.

Mar 26, 2014 at 9:11AM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Let's take a look at four stocks -- Insmed (NASDAQ:INSM), Exelixis (NASDAQ:EXEL), United Therapeutics (NASDAQ:UTHR), and Alnylam (NASDAQ:ALNY) -- which could all loom large in health care headlines this morning.

Insmed's lung infection drug fails a mid-stage trial
Insmed is down 9% in premarket this morning after reporting that its lung infection drug, Arikayce/Arikace, failed to meet the main goal of a phase 2 trial on patients with nontuberculous mycobacterial lung infections. Insmed does not have any marketed products.

This setback is a devastating blow for Insmed, since Arikayce is the company's only pipeline product. The drug was being tested for three kinds of lung infections. The most advanced indication, pseudomonas aeruginosa lung infections in cystic fibrosis patients, has reached phase 3 trials in Europe and Canada. The third indication, for pseudomonas aeruginosa lung infections in non-cystic fibrosis patients, has completed a phase 2 study.

Piper Jaffray, which reiterated its Overweight rating on the stock, noted that although the study failed to meet its primary endpoint, it met a "much more meaningful and clinically relevant" secondary endpoint of culture conversion.

Exelixis plunges after reporting the completion of an interim analysis
Meanwhile, Exelixis, which just reported the European approval of Cometriq yesterday, is down 30% in premarket this morning. Exelixis announced that an Independent Data Monitoring Committee (IDMC) had notified the company that a planned interim analysis of the COMET-1 phase 3 pivotal trial had been completed, and that the IDMC has recommended that the trial proceed to its final analysis. The company also stated that it continues to anticipate top-line data from the COMET-1 trial later this year.

COMET-1 is Exelixis' closely watched trial testing Cometriq as an advanced prostate cancer treatment, a potentially major indication for the drug.

United Therapeutics' Remodulin is approved in Japan
United Therapeutics just announced that Japan's Ministry of Health, Labor, and Welfare has approved Remodulin, its injected treatment for pulmonary arterial hypertension (PAH).

The drug will be sold in Japan under the brand name Treprost by Mochida Pharmaceutical, which previously signed an exclusive distribution agreement with United Therapeutics. Sales of Remodulin and Tyvaso, an inhaled version of the drug, accounted for 83% of the company's top line in fiscal 2013.

Orenitram, a new oral drug which contains the same active ingredient as Remodulin and Tyvaso, was approved last December and is expected to generate peak sales of $200 million to $300 million -- which could be a big boost for a company which reported $1.1 billion in revenues in 2013.

Sanofi boosts its investment in Alnylam
Last but not least, Sanofi's (NYSE:SNY) Genzyme unit just boosted its investment in Alnylam Pharmaceuticals, which studies RNAi therapeutics. Genzyme, which is focused on rare disease and multiple sclerosis treatments, exercised its right to buy 344,448 unregistered shares of Alnylam common stock.

Based on Alnylam's closing price of $66.88 on March 25, the transaction is valued at approximately $23 million. Genzyme now owns 12% of Alnylam's common stock. The two companies have been partnered since January in the development and commercialization of RNAi therapeutics as genetic medicines. Under that agreement, Genzyme purchased 8.8 million shares of new Alnylam stock for approximately $80 per share.

Alnylam doesn't have any marketed products, but its pipeline of a wide variety of genetically targeted treatments for amyloidosis, hemophilia, hypercholesterolemia, iron overload disorders, hyperlipidemia, and other indications.

Sanofi's investment in Alnylam is significant, since it has a history of investing in promising next generation technologies, such as its partnership with Regeneron in the development of fully human monoclonal antibodies. Sanofi recently considered raising its stake in Regeneron from 16% to 30%. This recent vote of confidence for Alnylam could increase bullish interest in the company, which has already rallied 180% over the past 12 months.


3 stocks that could become your next huge winner
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have done it before with the likes of Amazon and Netflix. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.

Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Alnylam Pharmaceuticals and Exelixis. The Motley Fool owns shares of Exelixis. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers